BioSpace News Archive

Supernus Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will present a company overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021, at 1:30 p.m. ET.

- Electromedical successfully launched its first practitioner testimonial event last week - Wednesday Facebook Live events feature doctor and patients championing WellnessPro Plus® benefits - Thursday Online Facetime meetings include new distributor on-boarding and training

Korro Bio, Inc. , an RNA editing company focused on the discovery and development of novel genetic medicines, today announced that Ram Aiyar, Ph.D., MBA, chief executive officer, will present at the 2021 Jefferies Virtual Healthcare Conference on June 4, 2021, at 2:30 p.m. EDT.

- Phase 3 Studies of Oral Insulin Underway and on Schedule - Oral COVID-19 Vaccine Clinical Trials Through Oravax Medical to Begin H2 2021

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that the company’s patent titled: “System and Method for High Throughput Screening of Cancer Cells” has been granted by the European Patent Office .

Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended March 31, 2021. Quarter 1 Results Total revenues for Q1, 2021 were $25.6m which compares to $21.2m in Q1, 2020, an increase of 20.9% and which were broken down as follows: 2020 Quarter 1 2021 Quarter 1 Increase/ (decrease)

Meeting essential requirements for marketing Bentrio TM in Europe under CE mark On track for first product launch in Europe towards end of Q2 2021

CollPlant, a regenerative and aesthetic medicine company, announced that its ordinary shares have been approved for trading on the Nasdaq Global Market® under the Company’s current ticker symbol “CLGN” and will begin trading at the open of market on June 4, 2021.

Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron”) today announced that it has sold $150 million of senior unsecured convertible promissory notes (the “Notes”) in a private placement transaction.

Seegrid Corporation, the leader in autonomous mobile robots (AMRs) for material handling, announced the formation of Blue Labs, a research and development group committed to furthering the company’s strong technical advantage.